Case Page

 

Case Status:    ONGOING    
On or around 10/26/2017 (Ongoing date of last review)

Filing Date: November 15, 2016

According to the law firm press release, Arrowhead is a biopharmaceutical company that develops novel drugs to treat intractable diseases in the United States. Among the Company’s products under development at all relevant times was ARC-520, an RNAi-based therapeutic in Phase IIb clinical efficacy studies to treat chronic hepatitis B virus infection.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) ARC-520 was fatal at certain doses; (ii) consequently, the U.S. Food & Drug Administration (“FDA”) was unlikely to approve ARC-520 as a hepatitis B treatment; (iii) Arrowhead had overstated the approval prospects and commercial viability of ARC-520; and (iv) as a result, Arrowhead’s public statements were materially false and misleading at all relevant times.

On November 8, 2016, post-market, Arrowhead issued a press release announcing that the FDA would be placing a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520, likely due to deaths at the highest dose of an ongoing non-human primate toxicology study.

On this news, Arrowhead’s share price fell $1.91, or 31.26%, to close at $4.20 on November 9, 2016.

On March 8, 2017, the Court appointed Lead Plaintiff and Counsel. A consolidated complaint was filed on April 28.

On September 20, 2017, the Court granted the Motion to dismiss with leave to amend. An amended complaint was filed on October 26.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ARWR
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: C.D. California
DOCKET #: 16-CV-08505
JUDGE: Hon. Philip S. Gutierrez
DATE FILED: 11/15/2016
CLASS PERIOD START: 05/11/2015
CLASS PERIOD END: 11/08/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Pomerantz LLP (New York)
    600 Third Avenue, Pomerantz LLP (New York), NY 10016
    212.661.1100 212.661.8665 · info@pomerantzlaw.com/
No Document Title Filing Date
COURT: C.D. California
DOCKET #: 16-CV-08505
JUDGE: Hon. Philip S. Gutierrez
DATE FILED: 10/26/2017
CLASS PERIOD START: 01/12/2015
CLASS PERIOD END: 11/29/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Levi & Korsinsky (Los Angeles)
    445 South Figueroa Street, 31st Floor, Levi & Korsinsky (Los Angeles), CA 90071
    (213) 985-7290 (202) 333-2121 ·
No Document Title Filing Date